Innova Captab Limited (IN:INNOVACAP)
:INNOVACAP
Want to see IN:INNOVACAP full AI Analyst Report?
INNOVACAP Stock Chart & Stats
₹723.20
-₹52.30(-4.22%)
At close: 4:00 PM EST
₹723.20
-₹52.30(-4.22%)
Day’s Range― - ―
52-Week Range₹608.25 - ₹1,002.95
Previous CloseN/A
Volume127.60K
Average Volume (3M)1.70K
Market Cap
₹41.82B
Enterprise Value₹44.46B
Total Cash (Recent Filing)₹584.35M
Total Debt (Recent Filing)₹3.36B
Price to Earnings (P/E)24.4
Beta0.84
Next Earnings
Jun 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.37
Shares Outstanding57,224,930
10 Day Avg. Volume1,138
30 Day Avg. Volume1,704
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)5.33
Price to Sales (P/S)4.11
P/FCF Ratio-47.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33
Revenue Forecast (FY)₹19.25B
Bulls Say, Bears Say
Bulls Say
Robust Revenue GrowthSustained ~25.6% revenue growth indicates durable demand and successful market penetration in finished dosages and CDMO services. Over 2-6 months this supports higher capacity utilisation, stronger contract leverage and a rising top line that can fund margin improvements and strategic investments.
Material Margin ExpansionSignificant improvement in gross and net margins reflects structural production efficiency gains and better product mix. Higher gross margins suggest sustainable cost advantages and scale economics that bolster long-term profitability and resilience versus cyclic pressures in the pharma manufacturing sector.
Prudent Balance Sheet And LeverageA strong equity base and low D/E provide financial flexibility and lower refinancing risk, enabling capex or selective bolt-on investments without overleveraging. Improved ROE shows efficient use of capital, supporting sustainable growth and creditor confidence over the medium term.
Bears Say
Weak Cash ConversionOCF covering only half of reported net income signals that earnings are not fully converted to cash. Persistently weak cash conversion can constrain working capital, limit self-funded growth and raise reliance on external financing, posing a durable operational risk to liquidity and execution.
Negative Free Cash FlowOngoing negative free cash flow, despite recent improvement, restricts the company's ability to reinvest, pay down debt or return capital. If sustained, it may force external funding for growth capex or working capital and limit strategic optionality over the coming quarters.
EPS Growth Lags RevenueEPS grew only ~3.9% while revenue rose ~25.6%, suggesting earnings quality issues, dilution, or lagging operating leverage. Converting top-line gains into bottom-line EPS is essential; failure to do so would weaken shareholder returns and indicate structural inefficiencies over the medium term.
Innova Captab Limited News
INNOVACAP FAQ
What was Innova Captab Limited’s price range in the past 12 months?
Innova Captab Limited lowest stock price was ₹608.25 and its highest was ₹1002.95 in the past 12 months.
What is Innova Captab Limited’s market cap?
Innova Captab Limited’s market cap is ₹41.82B.
When is Innova Captab Limited’s upcoming earnings report date?
Innova Captab Limited’s upcoming earnings report date is Jun 03, 2026 which is in 34 days.
How were Innova Captab Limited’s earnings last quarter?
Innova Captab Limited released its earnings results on Jan 23, 2026. The company reported ₹7.366 earnings per share for the quarter, beating the consensus estimate of N/A by ₹7.366.
Is Innova Captab Limited overvalued?
According to Wall Street analysts Innova Captab Limited’s price is currently Overvalued.
Does Innova Captab Limited pay dividends?
Innova Captab Limited does not currently pay dividends.
What is Innova Captab Limited’s EPS estimate?
Innova Captab Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Innova Captab Limited have?
Innova Captab Limited has 57,224,930 shares outstanding.
What happened to Innova Captab Limited’s price movement after its last earnings report?
Innova Captab Limited reported an EPS of ₹7.366 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.265%.
Which hedge fund is a major shareholder of Innova Captab Limited?
Currently, no hedge funds are holding shares in IN:INNOVACAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Innova Captab Limited
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also involved in the development, manufacture, and distribution of generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial, erectile dysfunction, anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through its network of distributors and pharmacies, as well as online through various e-commerce pharmacy sites. The company was incorporated in 2005 and is based in Panchkula, India.
Technical Analysis
Bliss Gvs Pharma Limited
―
Gufic Biosciences Limited
―
Morepen Laboratories Limited
―
Orchid Pharma Limited
―
Unichem Laboratories Limited
―